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n resource-limited settings, there 
is a high risk of mother-to-child-
transmission (MTCT) of HIV-1. 
The rate of MTCT without speciﬁ  c 
intervention and with an extended 
time of breast-feeding is about 35%–
40% [1], a ﬁ  gure that results in the 
infection of about 750,000 children 
every year worldwide [2]. A single dose 
of nevirapine can reduce the rate of 
MTCT by 42%, but it selects for drug-
resistant variants in as many as 75% of 
mothers receiving this treatment [3]. 
As multiple-drug treatment is rarely 
available in developing countries, 
and breast-feeding often continues 
for at least two years after delivery, 
the concept of preventing MTCT 
transmission by passive administration 
of antibodies, by the use of antibodies 
and drugs, or by the use of combined 
active–passive immunization is 
attracting increasing attention [4]. 
Studies of Passive Immunization
Passive immunization experiments 
have proven that antibodies can protect 
against HIV-1 infection in animal 
models. Polyclonal or monoclonal 
antibodies (mAbs) against simian 
immunodeﬁ  ciency virus (SIV) or 
HIV-1 have mediated protection of 
chimpanzees from HIV-1 infection 
[5] and protection of juvenile and 
neonatal macaques from infection with 
SIV or with chimeric simian/human 
immunodeﬁ  ciency virus (SHIV) 
[6–10]. In several experiments with 
SHIV89.6P, broadly neutralizing 
human mAbs b12, 2G12, 2F5, and 
4E10 were tested [6,7,9,10]. These 
mAbs were generated from subtype-
B-infected individuals. Although 
HIV-1 subtype B is the predominant 
subtype in North America, Western 
Europe, and Australia, HIV-1 subtype 
B viruses account for only about 12% 
of the global HIV pandemic [11]. The 
mAbs tested in these experiments 
react with epitopes in the CD4 binding 
domain of gp120 (mAb b12), with 
gp120 glycans (mAb 2G12), and with 
epitopes in the membrane proximal 
region of gp41 (mAbs 2F5 and 4E10). 
A combination of these mAbs provided 
a stronger protective effect than any 
of the single mAbs, which individually 
mediated only partial protection at 
best against chimeric simian/human 
immunodeﬁ  ciency virus [6]. 
The evidence for the function of 
anti-HIV-1 antibodies in preventing 
MTCT in humans is less conclusive 
than in animal models. Early studies 
showed a positive correlation between 
the presence of neutralizing antibodies 
in mothers and lower incidence 
of MTCT [12,13], although more 
recently these ﬁ  ndings have not been 
replicated [14]. Moreover, there are 
few data on the effectiveness of passive 
immunization in the prevention of 
MTCT in humans. Only one study 
reported the use in HIV-infected 
pregnant women of HIVIG, an immune 
globulin preparation from HIV-
infected individuals containing high 
levels of anti-HIV-1 antibodies. This 
clinical trial was inconclusive because 
of the overall low transmission rate 
in the study groups, but it showed 
an intriguing trend toward lower 
transmission with HIVIG than with 
control immunoglobulin [15]. 
A New mAb Study 
In a new paper published in PLoS 
Medicine, Gray et al. address the 
question of whether human anti-HIV 
mAbs 2F5, 2G12, b12, and 4E10 might 
be useful in South Africa as reagents 
to prevent MTCT of subtype C viruses 
[16]. To examine this question, 
they tested these mAbs, which had 
previously been used in monkey passive 
immunization studies (see above), 
for their ability to neutralize in vitro 
seven subtype C primary isolates from 
pediatric patients. The study shows 
that two of the mAbs, 2G12 and 2F5, 
had no neutralizing activity against the 
subtype C isolates tested. The authors 
conclude that these two mAbs should 
not proceed into passive immunization 
clinical trials in southern Africa and 
other regions where HIV-1 subtype 
C viruses predominate. Of the other 
two mAbs tested, b12 and 4E10, the 
former was shown to be potent, with 
a 50% neutralizing dose in the range 
of 0.2 to 11.9 µg mAb/ml, but capable 
of neutralizing only four of the seven 
isolates; in contrast, 4E10 lacked 
potency, requiring up to 46 µg mAb/
ml to achieve 50% neutralization, but it 
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eventually neutralized all of the isolates 
tested. 
Although mAbs b12 and 4E10 did 
display neutralizing activity against 
subtype C viruses, these mAbs have 
recently been shown to have the 
characteristics of polyspeciﬁ  c and 
auto-reactive antibodies. Thus, mAb 
b12 recognizes the CD4 binding site 
of gp120 as well as ribonucleoproteins, 
double-stranded DNA, centromere B 
antigens, histones, and cytoplasmic 
and nucleolar antigens of HEp-2 cells. 
Similarly, mAb 4E10 recognizes an 
epitope in the membrane proximal 
region of gp41 and also binds to 
host antigens including cardiolipin, 
phospholipids, lupus erythematosus 
autoantigen SS-A/Ro, and cytoplasmic 
and nuclear antigens of HEp-2 cells, 
and has lupus anticoagulant reactivity 
[17]. Crystallographic analysis of the 
complex of the Fab fragment of 4E10 
with gp41 peptide showed that the 
CDR H3 has no contact with the gp41 
peptide [18], suggesting that the CDR 
H3, which is the major loop of the 
antibody binding site involved in the 
interaction with antigen, might interact 
with membrane components such as 
phospholipids. 
To date, there are no published 
data that suggest that these particular 
mAbs with autoreactive activity are 
pathogenic. Indeed, mAbs 4E10, 
2G12, and 2F5 were tested as reagents 
for passive immunotherapy in HIV-
infected individuals and no toxicity was 
observed [19]. mAb 4E10, however, 
did not reach the same plasma level 
as mAb 2G12 in this clinical trial 
and did not induce escape mutants 
as did 2G12, suggesting that mAb 
4E10 could have been absorbed 
out by host antigens [19]. Concern 
is compounded by the observation 
that anti-cardiolipin antibodies are 
associated with thrombosis and 
procoagulopathies [20], indicating that 
the risk assessment for antibodies with 
autoreactive characteristics must be 
stringent, especially when use in infants 
is contemplated.
Clinical Implications
In summary, the accumulated data 
suggest that although antibodies have 
a role in preventing or decreasing the 
rate of MTCT of HIV-1, the human 
anti-HIV mAbs currently available 
will not sufﬁ  ce as reagents for passive 
immunization in most parts of the 
developing world, where subtype B 
viruses (the subtype most effectively 
targeted by most of the currently 
available human mAbs) are rare. 
Currently, there is a critical need to 
determine if passive immunization with 
HIVIG will deﬁ  nitively decrease MTCT, 
and if so, there needs to be a concerted 
effort to develop the speciﬁ  c mAbs 
to be used alone, in combination, or 
together with antiretroviral drugs to 
prevent the infection of infants.  
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